Tag: Opdiva
Nivolumab and DS-8201 to be Evaluated in HER2-Expressing Breast and Bladder...
Bristol-Myers Squibb and Daiichi Sankyo have agreed to collaborate in a clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy nivolumab (Opdivo®) and...
Immune Checkpoint Inhibitor Nivolumab: Five-year Survival Rate in Advanced Lung Cancer
Data from a phase I clincal trial presented at the Annual Meeting of American Association for Cancer Research (AACR), beimg held April 1-5, 2017...
